Core Insights - Scienture Holdings, Inc. has formalized multiple Group Purchasing Organization (GPO) agreements for its naloxone product, REZENOPY, which is expected to penetrate approximately 60% of the U.S. institutional market [1][2] - The U.S. naloxone market is valued at approximately $141 million annually, with 9.4 million prescription units, presenting a significant commercial opportunity for REZENOPY [1][3] - REZENOPY is the highest-dose FDA-approved naloxone nasal spray, designed for emergency treatment of opioid overdoses, and is positioned to drive broader adoption and market share [2][3] Company Overview - Scienture Holdings, Inc. focuses on developing and commercializing specialty pharmaceutical products that address unmet market needs, enhancing value for patients, physicians, and caregivers [8] - The company operates through its wholly-owned subsidiary, Scienture, LLC, which is dedicated to bringing unique specialty products to market [8] Product Information - REZENOPY (naloxone HCl) Nasal Spray 10 mg is indicated for emergency treatment of known or suspected opioid overdose, intended for immediate administration in settings where opioids may be present [4][5] - The product is supplied as a carton containing two blister packages, each with a single spray device [4]
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions